Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor

Yoonkyung Do, Arnaud M. Didierlaurent, Seongho Ryu, Hyein Koh, Chae Gyu Park, Steven Park, David S. Perlin, Bradford S. Powell, Ralph M. Steinman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

It is of great interest to develop a pneumonic plague vaccine that would induce combined humoral and cellular immunity in the lung. Here we investigate a novel approach based on targeting of dendritic cells using the DEC-205/CD205 receptor (DEC) via the intranasal route as way to improve mucosal cellular immunity to the vaccine. Intranasal administration of Yersinia pestis LcrV (V) protein fused to anti-DEC antibody together with poly IC as an adjuvant induced high frequencies of IFN-γ secreting CD4+ T cells in the airway and lung as well as pulmonary IgG and IgA antibodies. Anti-DEC:LcrV was more efficient to induce IFN-γ/TNF-α/IL-2 secreting polyfunctional CD4+ T cells when compared to non-targeted soluble protein vaccine. In addition, the intranasal route of immunization with anti-DEC:LcrV was associated with improved survival upon pulmonary challenge with the virulent CO92 Y. pestis. Taken together, these data indicate that targeting dendritic cells via the mucosal route is a potential new avenue for the development of a mucosal vaccine against pneumonic plague.

Original languageEnglish (US)
Pages (from-to)6359-6367
Number of pages9
JournalVaccine
Volume30
Issue number45
DOIs
StatePublished - Oct 5 2012

Fingerprint

mucosal immunity
Mucosal Immunity
Vaccines
lungs
vaccines
Lung
receptors
Plague
Cellular Immunity
Dendritic Cells
Yersinia pestis
Plague Vaccine
Proteins
proteins
plague
dendritic cells
T-Lymphocytes
Intranasal Administration
cell-mediated immunity
Humoral Immunity

All Science Journal Classification (ASJC) codes

  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Molecular Medicine
  • Immunology and Microbiology(all)

Keywords

  • CD205/DEC-205
  • Cellular immunity
  • Dendritic cells
  • LcrV
  • Mucosal
  • Y. pestis

Cite this

Do, Y., Didierlaurent, A. M., Ryu, S., Koh, H., Park, C. G., Park, S., ... Steinman, R. M. (2012). Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine, 30(45), 6359-6367. https://doi.org/10.1016/j.vaccine.2012.08.051
Do, Yoonkyung ; Didierlaurent, Arnaud M. ; Ryu, Seongho ; Koh, Hyein ; Park, Chae Gyu ; Park, Steven ; Perlin, David S. ; Powell, Bradford S. ; Steinman, Ralph M. / Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. In: Vaccine. 2012 ; Vol. 30, No. 45. pp. 6359-6367.
@article{3157b959d0d64b0297f610849374fde9,
title = "Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor",
abstract = "It is of great interest to develop a pneumonic plague vaccine that would induce combined humoral and cellular immunity in the lung. Here we investigate a novel approach based on targeting of dendritic cells using the DEC-205/CD205 receptor (DEC) via the intranasal route as way to improve mucosal cellular immunity to the vaccine. Intranasal administration of Yersinia pestis LcrV (V) protein fused to anti-DEC antibody together with poly IC as an adjuvant induced high frequencies of IFN-γ secreting CD4+ T cells in the airway and lung as well as pulmonary IgG and IgA antibodies. Anti-DEC:LcrV was more efficient to induce IFN-γ/TNF-α/IL-2 secreting polyfunctional CD4+ T cells when compared to non-targeted soluble protein vaccine. In addition, the intranasal route of immunization with anti-DEC:LcrV was associated with improved survival upon pulmonary challenge with the virulent CO92 Y. pestis. Taken together, these data indicate that targeting dendritic cells via the mucosal route is a potential new avenue for the development of a mucosal vaccine against pneumonic plague.",
keywords = "CD205/DEC-205, Cellular immunity, Dendritic cells, LcrV, Mucosal, Y. pestis",
author = "Yoonkyung Do and Didierlaurent, {Arnaud M.} and Seongho Ryu and Hyein Koh and Park, {Chae Gyu} and Steven Park and Perlin, {David S.} and Powell, {Bradford S.} and Steinman, {Ralph M.}",
year = "2012",
month = "10",
day = "5",
doi = "https://doi.org/10.1016/j.vaccine.2012.08.051",
language = "English (US)",
volume = "30",
pages = "6359--6367",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "45",

}

Do, Y, Didierlaurent, AM, Ryu, S, Koh, H, Park, CG, Park, S, Perlin, DS, Powell, BS & Steinman, RM 2012, 'Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor', Vaccine, vol. 30, no. 45, pp. 6359-6367. https://doi.org/10.1016/j.vaccine.2012.08.051

Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. / Do, Yoonkyung; Didierlaurent, Arnaud M.; Ryu, Seongho; Koh, Hyein; Park, Chae Gyu; Park, Steven; Perlin, David S.; Powell, Bradford S.; Steinman, Ralph M.

In: Vaccine, Vol. 30, No. 45, 05.10.2012, p. 6359-6367.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor

AU - Do, Yoonkyung

AU - Didierlaurent, Arnaud M.

AU - Ryu, Seongho

AU - Koh, Hyein

AU - Park, Chae Gyu

AU - Park, Steven

AU - Perlin, David S.

AU - Powell, Bradford S.

AU - Steinman, Ralph M.

PY - 2012/10/5

Y1 - 2012/10/5

N2 - It is of great interest to develop a pneumonic plague vaccine that would induce combined humoral and cellular immunity in the lung. Here we investigate a novel approach based on targeting of dendritic cells using the DEC-205/CD205 receptor (DEC) via the intranasal route as way to improve mucosal cellular immunity to the vaccine. Intranasal administration of Yersinia pestis LcrV (V) protein fused to anti-DEC antibody together with poly IC as an adjuvant induced high frequencies of IFN-γ secreting CD4+ T cells in the airway and lung as well as pulmonary IgG and IgA antibodies. Anti-DEC:LcrV was more efficient to induce IFN-γ/TNF-α/IL-2 secreting polyfunctional CD4+ T cells when compared to non-targeted soluble protein vaccine. In addition, the intranasal route of immunization with anti-DEC:LcrV was associated with improved survival upon pulmonary challenge with the virulent CO92 Y. pestis. Taken together, these data indicate that targeting dendritic cells via the mucosal route is a potential new avenue for the development of a mucosal vaccine against pneumonic plague.

AB - It is of great interest to develop a pneumonic plague vaccine that would induce combined humoral and cellular immunity in the lung. Here we investigate a novel approach based on targeting of dendritic cells using the DEC-205/CD205 receptor (DEC) via the intranasal route as way to improve mucosal cellular immunity to the vaccine. Intranasal administration of Yersinia pestis LcrV (V) protein fused to anti-DEC antibody together with poly IC as an adjuvant induced high frequencies of IFN-γ secreting CD4+ T cells in the airway and lung as well as pulmonary IgG and IgA antibodies. Anti-DEC:LcrV was more efficient to induce IFN-γ/TNF-α/IL-2 secreting polyfunctional CD4+ T cells when compared to non-targeted soluble protein vaccine. In addition, the intranasal route of immunization with anti-DEC:LcrV was associated with improved survival upon pulmonary challenge with the virulent CO92 Y. pestis. Taken together, these data indicate that targeting dendritic cells via the mucosal route is a potential new avenue for the development of a mucosal vaccine against pneumonic plague.

KW - CD205/DEC-205

KW - Cellular immunity

KW - Dendritic cells

KW - LcrV

KW - Mucosal

KW - Y. pestis

UR - http://www.scopus.com/inward/record.url?scp=84866547636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866547636&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.vaccine.2012.08.051

DO - https://doi.org/10.1016/j.vaccine.2012.08.051

M3 - Article

VL - 30

SP - 6359

EP - 6367

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 45

ER -